進行・再発胃癌治療レジメン

出版社: 医学と看護社
著者:
発行日: 2020-11-05
分野: 臨床医学:一般  >  癌/腫瘍一般
ISBN: 9784909888174
電子書籍版: 2020-11-05 (第1版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:4~8営業日

3,190 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,190 円(税込)

目次

  • 1.はじめに
    2.治療適応
    3.レジメン決定のための検査
    4.遺伝子パネル検査
    5.胃癌化学療法におけるキードラッグと治療アルゴリズム概略
    6.一次化学療法の概略
    7.一次化学療法の具体的レジメン選択
    8.二次化学療法の概略
    9.高頻度マイクロサテライト不安定性(MSI-High)
    10.二次化学療法の具体的レジメン選択
    11.補助化学療法後早期再発
    12.三次化学療法以降の概略
    13.三次化学療法以降の具体的レジメン選択
    14.キードラッグの使い切り
    15.治療ライン切り替え
    16.化学療法時の栄養介入
    17.化学療法中の手術介入

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

文献

P.58 掲載の参考文献
1) 日本胃癌学会編. 胃癌治療ガイドライン医師用 第5版, 金原出版 ; 2018
2) 大腸癌研究会編. 大腸癌治療ガイドライン医師用 2019年版, 金原出版 ; 2019
3) 日本病理学会編. 胃癌・乳癌HER2病理診断ガイドライン 第1版, 金原出版 ; 2015
4) 日本胃癌学会. 胃癌治療ガイドライン 速報版 2019年3月
5) MSI検査キット (FALCO) 添付文書 マイクロサテライト不安定性検出キット 製造販売承認番号 : 23000 EZX00047000
6) Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014 ; 513 : 202-9
7) Shitara K, Ozguro?lu M, Bang YJ, et al ; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061) : a randomised, open-label, controlled, phase 3 trial. Lancet 2018 ; 392 : 123-33
8) OncoGuideTM NCC オンコパネル システム 添付文書 機械器具 17 血液検査用器具 その他の医用検体検査装置 高度管理医療機器 遺伝子変異解析セット (がんゲノムプロファイリング検査用) (60943013)
9) FoundationOne(R) CDxがんゲノムプロファイル 添付文書 プログラム 1 疾病診断用プログラム 高度管理医療機器 遺伝子変異解析プログラム (がんゲノムプロファイリング検査用) JMDNコード : 60943023 〔体細胞遺伝子変異解析プログラム (抗悪性腫瘍薬適応判定用) JMDNコード : 70159013〕
10) Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 2015 ; 26 : 141-8
11) Kimura Y, Fujii M, Masuishi T, et al. Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06). Gastric Cancer 2018 ; 21 : 421-7
12) Fujitani K, Yang HK, Mizusawa J, et al ; REGATTA study investigators. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA) : a phase 3, randomised controlled trial. Lancet Oncol 2016 ; 17 : 309-18
13) Bando H, Yamada Y, Tanabe S, et al. Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer. Gastric Cancer 2016 ; 19 : 919-26
14) Tamura T, Sasaki Y, Nishiwaki Y, et al. Phase I study of paclitaxel by three-hour infusion : hypotension just after infusion is one of the major dose-limiting toxicities. Jpn J Cancer Res 1995 ; 86 : 1203-9
15) タキソテール点滴静注用添付文書
16) 岡秀男, 佐々木常雄, 下山孝. 慢性腎不全患者における5-FU急速静注時の血中動態. J Jpn Soc Cancer Ther 1997 ; 32 : 20-6
17) 岸本武利監修. 透析患者への投薬ガイドブック, 薬業時報社, 東京 ; 1999 : 309-21
18) Rebibou JM, Chauffert B, Dumas M, et al. Combined chemotherapy and radiotherapy for esophageal carcinoma in a hemodialyzed patient. Longterm survival. Nephron 1996 ; 74 : 611-2
19) 長晴彦, 今田敏夫, 益戸功彦, 他. 5-FU+CDDP療法を施行した人工透析中の胃癌症例. 癌と化学療法 2000 ; 27 : 2135-8
20) Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer 2012 ; 48 : 518-26
21) Nishikawa K, Tsuburaya A, Yoshikawa T, et al. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer : Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II). Eur J Cancer 2018 ; 101 : 220-8
22) Kawakami H, Takeno A, Endo S, et al. Randomized, Open-Label Phase II Study Comparing Capecitabine-Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-Naive Patients with HER2-Negative Advanced Gastric Cancer : OGSG1105, HERBIS-4 A Trial. Oncologist 2018 ; 23 : 1411-e147
23) Wilke H, Muro K, Van Cutsem E, et al ; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW) : a double-blind, randomised phase 3 trial. Lancet Oncol 2014 ; 15 : 1224-35
24) Shitara K, Muro K, Shimada Y, et al. Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW : a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer 2016 ; 19 : 927-38
25) Bando H, Shimodaira H, Fujitani K, et al. A phase II study of nabpaclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. Eur J Cancer 2018 ; 91 : 86-91
26) Diaz LA Jr, Marabelle A, Delord JP, et al. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. J Clin Oncol 2017 ; 35 (15 suppl) : 3071
27) Shitara K, Takashima A, Fujitani K, et al. Nab-paclitaxel versus solventbased paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE) : an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol 2017 ; 2 : 277-87
28) Makiyama A, Sukawa Y, Kashiwada T, et al. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer : WJOG7112G (T-ACT Study). J Clin Oncol 2020 ; 38 : 1919-27
29) Shitara K, Morita S, Fujitani K, et al. Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1 : multi-institutional retrospective analysis. Gastric Cancer 2012 ; 15 : 245-51
30) Nishikawa K, Murotani K, Fujitani K, et al. Differences in disease status between patients with progression after first-line chemotherapy versus early relapse after adjuvant chemotherapy who undergo second-line chemotherapy for gastric cancer : Exploratory analysis of the randomized phase III TRICS trial. Eur J Cancer 2020 ; 132 : 159-67
31) Nishikawa K, Murotani K, Fujitani K, et al. A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naive patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy : exploratory subgroup analysis of the randomized phase III TRICS trial. Cancer Chemother Pharmacol 2019 ; 83 : 867-74
32) Tanabe K, Fujii M, Nishikawa K, et al. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05). Ann Oncol 2015 ; 26 : 1916-22
33) Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017 ; 390 : 2461-71
34) Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS) : a randomised, double-blind, placebo- controlled, phase 3 trial. Lancet Oncol 2018 ; 19 : 1437-48
35) 日本胃癌学会. 胃癌ガイドライン速報版 2019年9月
36) Nishikawa K, Morita S, Matsui T, et al. A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer. Gastric Cancer 2012 ; 15 : 363-9
37) Tsuburaya A, Yoshida K, Kobayashi M, et al. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4 a/b gastric cancer (SAMIT) : a phase 3 factorial randomised controlled trial. Lancet Oncol 2014 ; 15 : 886-93
38) Iizumi S, Takashima A, Sakamaki K, et al. Survival impact of postprogression chemotherapy in advanced gastric cancer : systematic review and meta-analysis. Cancer Chemother Pharmacol 2018 ; 81 : 981-9
39) Hasegawa H, Fujitani K, Nakazuru S, et al. Optimal treatment change criteria for advanced gastric cancer with non-measurable peritoneal metastasis : symptom/tumor marker-based versus CT-based. Anticancer Res 2014 ; 34 : 5169-74
40) Takayoshi K, Uchino K, Nakano M, et al. Weight Loss During Initial Chemotherapy Predicts Survival in Patients With Advanced Gastric Cancer. Nutr Cancer 2017 ; 69 : 408-15
41) Sugiyama K, Narita Y, Mitani S, et al. Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer. Anticancer Res 2018 ; 38 : 5859-66
42) Mansoor W, et al. Abstracts in the 2019 World GI Abstract Supplement (30_Supplement 4). Ann Oncol 2019 ; 30 (Suppl_4) : PD-005
43) Imamura H, Nishikawa K, Kishi K, et al. Effects of an Oral Elemental Nutritional Supplement on Post-gastrectomy Body Weight Loss in Gastric Cancer Patients : A Randomized Controlled Clinical Trial. Ann Surg Oncol 2016 ; 23 : 2928-35
44) Kimura Y, Nishikawa K, Kishi K, et al. Long-term effects of an oral elemental nutritional supplement on post-gastrectomy body weight loss in gastric cancer patients (KSES002). Ann Gastroenterol Surg 2019 ; 3 : 648-56

最近チェックした商品履歴

Loading...